Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study

NCT07607587 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT07607587
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07607587 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Recruiting
Start date
May 29, 2026
Completion date
November 19, 2027
Enrollment
114 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight